Back to Results
First PageMeta Content
Science / Clinical research / Design of experiments / Evaluation methods / Food and Drug Administration / FDA Special Protocol Assessment / Clinical trial / Ultrasound / Pharmacovigilance / Medicine / Pharmacology / Pharmaceutical sciences


ACUSPHERE INC. REACHES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR IMAGIFY™ PHASE 3 PLACEBO-CONTROLLED TRIAL LEXINGTON, MASS., June 8, [removed]Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, today
Add to Reading List

Document Date: 2011-10-26 19:37:10

Open Document

File Size: 78,72 KB

Share Result on Facebook

Company

ACUSPHERE INC. / /

Country

United States / /

Currency

USD / /

Event

FDA Phase / /

Facility

SPA Process / /

IndustryTerm

agreed-upon clinical trial protocol / pharmaceutical / stress imaging tests / /

MedicalCondition

cancer / coronary artery disease / /

MedicalTreatment

radiation / /

Organization

FDA / European Union / European Medicines Agency / U.S. Food & Drug Administration / /

Person

Sherri C. Oberg / /

Position

President and Chief Executive Officer / /

Product

Injectable Suspension / Imagify / Imagify™ Perflubutane Polymer Microspheres / FDA FOR IMAGIFY™ / /

ProvinceOrState

Massachusetts / /

Technology

radiation / ultrasound / agreed-upon clinical trial protocol / CAD / /

URL

www.acusphere.com / /

SocialTag